YU37301A - Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa - Google Patents

Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa

Info

Publication number
YU37301A
YU37301A YU37301A YU37301A YU37301A YU 37301 A YU37301 A YU 37301A YU 37301 A YU37301 A YU 37301A YU 37301 A YU37301 A YU 37301A YU 37301 A YU37301 A YU 37301A
Authority
YU
Yugoslavia
Prior art keywords
pharmaceutical composition
modified release
insulin sensitiser
antidiabetic agent
another antidiabetic
Prior art date
Application number
YU37301A
Other languages
English (en)
Inventor
Karen Lewis
Nicola Lilliott
Donald Colin Mackenzie
Vincenzo Re
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547326&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU37301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9824867.7A external-priority patent/GB9824867D0/en
Priority claimed from GBGB9824866.9A external-priority patent/GB9824866D0/en
Priority claimed from GBGB9824869.3A external-priority patent/GB9824869D0/en
Priority claimed from GBGB9912190.7A external-priority patent/GB9912190D0/en
Priority claimed from GBGB9912193.1A external-priority patent/GB9912193D0/en
Priority claimed from GBGB9912191.5A external-priority patent/GB9912191D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of YU37301A publication Critical patent/YU37301A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Farmaceutski preparat, koji sadrži: sensitizer insulina i drugi antidijabetski agens i farmaceutski prihvatljiv nosač, gde je preparat uredjen da obezbedi modifikovano oslobadjanje od bar jednog sensitizera insulina i drugog antidijabetskog agensa, i korišćenje takvog preparata u medicini.[A pharmaceutical composition, which composition comprises: an insulin sensitiser and another antidiabetic agent and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of at least one of the insulin sensitiser and the other antidiabetes agent, and the use of such composition in medicine.
YU37301A 1998-11-12 1999-11-08 Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa YU37301A (sh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9824867.7A GB9824867D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9824866.9A GB9824866D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9824869.3A GB9824869D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912190.7A GB9912190D0 (en) 1999-05-25 1999-05-25 Novel composition and use
GBGB9912193.1A GB9912193D0 (en) 1999-05-25 1999-05-25 Novel composition and use
GBGB9912191.5A GB9912191D0 (en) 1999-05-25 1999-05-25 Novel composition and use

Publications (1)

Publication Number Publication Date
YU37301A true YU37301A (sh) 2005-06-10

Family

ID=27547326

Family Applications (1)

Application Number Title Priority Date Filing Date
YU37301A YU37301A (sh) 1998-11-12 1999-11-08 Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa

Country Status (36)

Country Link
EP (3) EP1131070B1 (sh)
JP (1) JP2002529504A (sh)
KR (1) KR100643833B1 (sh)
CN (1) CN1230162C (sh)
AR (1) AR024228A1 (sh)
AT (1) ATE406889T1 (sh)
AU (1) AU768994B2 (sh)
BG (2) BG109852A (sh)
BR (1) BR9915285A (sh)
CA (1) CA2351058A1 (sh)
CY (1) CY1108587T1 (sh)
CZ (1) CZ20011629A3 (sh)
DE (1) DE69939485D1 (sh)
DK (1) DK1131070T3 (sh)
DZ (1) DZ2936A1 (sh)
EA (2) EA011633B1 (sh)
ES (1) ES2312221T3 (sh)
HK (1) HK1040910B (sh)
HR (1) HRP20010343B1 (sh)
HU (1) HUP0104303A3 (sh)
ID (1) ID28783A (sh)
IL (2) IL143002A0 (sh)
MY (1) MY124695A (sh)
NO (1) NO20012303L (sh)
NZ (1) NZ511614A (sh)
OA (1) OA11677A (sh)
PE (1) PE20001238A1 (sh)
PL (1) PL347634A1 (sh)
PT (1) PT1131070E (sh)
SI (1) SI1131070T1 (sh)
SK (1) SK287038B6 (sh)
TR (1) TR200101333T2 (sh)
TW (2) TW592694B (sh)
UY (1) UY25799A1 (sh)
WO (1) WO2000028989A1 (sh)
YU (1) YU37301A (sh)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
AU2007201729B2 (en) * 1999-12-23 2010-02-25 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
SG149676A1 (en) * 1999-12-23 2009-02-27 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
US8257744B2 (en) * 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
CA2427195C (en) * 2000-11-03 2009-10-06 Andrx Corporation Controlled release metformin compositions
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
WO2002074285A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
FR2822069B1 (fr) * 2001-03-19 2003-06-20 Lipha Composition pharmaceutique comprenant un compose stimulant la secretion d'insuline et un derive de thiazolidinedione et son utilisation pour la preparation de medicamments destines a traiter le diabete
JP2004534056A (ja) * 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
AU2001273290B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. Core formulation comprising troglitazone and a biguanide
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
EP1474108A2 (en) 2002-01-09 2004-11-10 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
EP1515701B1 (en) * 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
CA2514879C (en) 2003-01-03 2014-09-16 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
KR101114808B1 (ko) 2003-01-29 2012-02-15 다케다 야쿠힌 고교 가부시키가이샤 피복 제제의 제조법
PE20050335A1 (es) * 2003-08-07 2005-06-01 Sb Pharmco Inc Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
US7700128B2 (en) 2003-10-31 2010-04-20 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
EP1741435A4 (en) * 2004-04-29 2009-11-11 Lotus Pharmaceutical Co Ltd ORAL VAPORS WITH MODIFIED RELEASE AND METHOD OF MANUFACTURING THEM
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
KR100657785B1 (ko) * 2005-02-19 2007-04-16 한국유나이티드제약 주식회사 글리메피리드, 메트포르민 및 은행엽엑스를 함유하는 약학적 조성물
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
MXPA05010977A (es) * 2005-10-12 2007-04-11 Abdala Leopoldo Espinosa Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus.
MXPA05014092A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
WO2007072992A2 (en) * 2005-12-22 2007-06-28 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
US20100081672A1 (en) * 2006-12-07 2010-04-01 Schering Corporation Ph sensitive matrix formulation
ATE476176T1 (de) * 2007-03-02 2010-08-15 Farnam Co Inc Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
KR20090013736A (ko) * 2007-08-02 2009-02-05 주식회사 한독약품 메트포르민 산 부가염을 포함하는 서방성 제제
HUE035130T2 (en) 2007-09-10 2018-05-02 Janssen Pharmaceutica Nv A method for preparing compounds useful as SGLT inhibitors
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
CN101548961B (zh) * 2008-04-03 2011-05-04 单宝华 一种治疗糖尿病及肥胖症的口服胶囊制剂
WO2010026467A2 (en) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
DK2488515T3 (en) 2009-10-14 2017-02-27 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2
MX339570B (es) 2010-05-11 2016-05-31 Janssen Pharmaceutica Nv Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
CN102970981A (zh) * 2010-07-06 2013-03-13 詹森药业有限公司 糖尿病协同治疗制剂
KR20140035331A (ko) 2011-01-07 2014-03-21 엘셀릭스 테라퓨틱스 인코포레이티드 화학감각 수용체 리간드-기반 요법
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
SI2697218T1 (sl) 2011-04-13 2016-07-29 Janssen Pharmaceutica Nv Postopek za pripravo spojin, koristnih kot zaviralci sglt2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
JP6175074B2 (ja) 2012-01-06 2017-08-02 エルセリクス セラピューティクス インコーポレイテッド 代謝障害を治療するための組成物および方法
CN102631332A (zh) * 2012-04-28 2012-08-15 邹立兴 一种伏格列波糖片剂及其制备方法
KR101409330B1 (ko) * 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
EP2958548A1 (en) * 2013-02-19 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. A production process for gliclazide formulations
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
US4538469A (en) * 1983-07-29 1985-09-03 Panametrics, Inc. Integrated threshold arming method and apparatus
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JP2630016B2 (ja) * 1990-05-21 1997-07-16 ヤマハ株式会社 吹奏感付加器を有する電子管楽器
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
KR930701436A (ko) 1990-07-03 1993-06-11 오노다 마사아이 비스헤테로환 화합물
HUT70153A (en) 1990-08-23 1995-09-28 Pfizer Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
HUT68370A (en) 1991-04-11 1995-06-28 Takeda Chemical Industries Ltd Thiazolidine derivatives, pharmaceutical compositions containing them and process for their production
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (sh) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
JPH07505647A (ja) 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 複素環化合物および２型糖尿病の治療におけるそれらの使用
WO1993022445A1 (en) 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
NZ253742A (en) 1992-07-03 1997-06-24 Smithkline Beecham Plc Heterocyclylaminoalkoxy substituted phenyl derivatives and pharmaceutical compositions
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
RU2071783C1 (ru) * 1993-09-07 1997-01-20 Ессентукский центральный военный санаторий Способ получения средства для лечения сахарного диабета
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
RU2114617C1 (ru) * 1996-09-27 1998-07-10 Юрий Георгиевич Каминский Антидиабетическое средство на основе янтарной кислоты
AU6576398A (en) * 1997-03-24 1998-10-20 Galderma Research & Development, S.N.C. Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment

Also Published As

Publication number Publication date
HRP20010343A2 (en) 2002-06-30
BR9915285A (pt) 2001-08-07
ID28783A (id) 2001-07-05
AR024228A1 (es) 2002-09-25
TW592694B (en) 2004-06-21
PL347634A1 (en) 2002-04-22
EP1131070A1 (en) 2001-09-12
WO2000028989A1 (en) 2000-05-25
BG105568A (en) 2002-01-31
CN1348369A (zh) 2002-05-08
ATE406889T1 (de) 2008-09-15
KR100643833B1 (ko) 2006-11-10
UY25799A1 (es) 2000-12-29
EA200601145A1 (ru) 2009-04-28
EA200100541A1 (ru) 2001-10-22
BG109852A (bg) 2008-11-28
DK1131070T3 (da) 2008-11-17
AU3033800A (en) 2000-06-05
DZ2936A1 (fr) 2004-03-15
SK6442001A3 (en) 2001-12-03
NZ511614A (en) 2003-12-19
HK1040910B (zh) 2009-06-26
PE20001238A1 (es) 2001-01-11
TR200101333T2 (tr) 2001-10-22
CA2351058A1 (en) 2000-05-25
EA007610B1 (ru) 2006-12-29
HUP0104303A3 (en) 2003-12-29
BG65351B1 (bg) 2008-03-31
AU768994B2 (en) 2004-01-15
HUP0104303A2 (hu) 2002-03-28
ES2312221T3 (es) 2009-02-16
NO20012303D0 (no) 2001-05-10
SK287038B6 (sk) 2009-10-07
PT1131070E (pt) 2008-11-19
HRP20010343B1 (en) 2010-11-30
CZ20011629A3 (cs) 2001-12-12
EP1131070B1 (en) 2008-09-03
EA011633B1 (ru) 2009-04-28
TW200418453A (en) 2004-10-01
EP1992337A1 (en) 2008-11-19
EP1813273A1 (en) 2007-08-01
HK1040910A1 (en) 2002-06-28
SI1131070T1 (sl) 2008-12-31
IL143002A (en) 2007-02-11
NO20012303L (no) 2001-07-04
DE69939485D1 (de) 2008-10-16
MY124695A (en) 2006-06-30
KR20010080419A (ko) 2001-08-22
IL143002A0 (en) 2002-04-21
JP2002529504A (ja) 2002-09-10
OA11677A (en) 2005-01-12
CY1108587T1 (el) 2014-04-09
TWI251487B (en) 2006-03-21
CN1230162C (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
YU37301A (sh) Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa
MY129356A (en) Electrospun pharmaceutical compositions
MY125516A (en) Novel composition based on thiazolidinedione and metformin and use
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
TW355683B (en) Composition containing micronized nebivolol
WO2002018327A3 (en) Guanidinobenzamides as mc4-r agonists
HRP20080117A2 (en) Pharmaceutical composition for modified release insulin sensitiser
AU2002231691A1 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
AU2084801A (en) Antiviral medication
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
FR2735369B1 (fr) Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
WO2002053090A3 (fr) Association medicamenteuse d'une biguanine (metformine) et d'arginine
GB9816899D0 (en) Therapeutic agents
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
AR019724A2 (es) Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
IL131267A0 (en) A medicament against infertility and for increasing fertility
JP2002500181A5 (sh)
AU2502301A (en) Medicament and combination of compatible medicaments
AU7370798A (en) Compositions and methods of therapy for igf-i-responsive conditions
ECSP993215A (es) Nueva composicion y uso
ECSP993216A (es) Nueva composicion y uso ii